ZYME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zymeworks Inc (ZYME) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong long-term growth potential, supported by favorable analyst ratings, a bullish technical trend, and a significant revenue increase. Despite short-term price fluctuations and negative net income, the company's strategic shift towards a royalty-focused model and upcoming catalysts make it a compelling long-term investment.
The technical indicators for ZYME are bullish. The MACD is positive and expanding, the RSI is neutral at 61.732, and the moving averages (SMA_5 > SMA_20 > SMA_200) indicate an upward trend. The stock is trading near its pivot level of 24.008, with resistance at 24.738 and support at 23.278.
Analysts have raised price targets significantly, with a consensus around $46-$48, citing strategic moves and upcoming catalysts.
The $250M debt deal with Royalty Pharma strengthens the company's balance sheet while retaining upside potential.
Revenue increased by 72.59% YoY in Q3 2025, showing strong growth.
Net income dropped by 34.33% YoY, and EPS declined by 33.33%, reflecting ongoing profitability challenges.
No significant hedge fund or insider trading trends, indicating a lack of strong institutional support.
In Q3 2025, Zymeworks reported a 72.59% YoY increase in revenue to $27.61M, indicating strong top-line growth. However, net income dropped to -$19.60M (-34.33% YoY), and EPS fell to -0.26 (-33.33% YoY), highlighting profitability challenges. Gross margin remained stable at 100%.
Analysts are highly bullish on ZYME, with multiple firms raising price targets to $46-$48 and maintaining Buy or Outperform ratings. Analysts highlight the company's strategic shift towards a royalty-focused model, favorable debt deal terms, and upcoming catalysts as key drivers for growth.
